Literature DB >> 581070

[Endogenous cortisol levels after intrathecal injection of triamicinolone acetonide in patients with neurological disease (author's transl)].

I Neu, E Reusche, S Rodiek.   

Abstract

A single dose of 40 mg triamcinolone acetonide was injected intrathecally in 30 patients with multiple sclerosis and 20 with other neurological diseases. In 15 of them the endogenous cortisol level was determined on three successive days and their cerebrospinal fluid examined before the triamcinolone injection was given. Cortisol levels were then measured serially for another 15 days after the injection. Contrary to the response after intramuscular injection, the endogenous secretion of cortisol was not significantly depressed after intrathecal administration. The latter is, therefore, suggested in the treatment of inflammatory diseases of the central nervous system and its integuments, and for acute exacerbations of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 581070     DOI: 10.1055/s-0028-1129265

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study.

Authors:  R Heun; U Sliwka; H Rüttinger; K Schimrigk
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

2.  Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms.

Authors:  Kerstin Hellwig; Franz Josef Stein; Horst Przuntek; Thomas Müller
Journal:  BMC Neurol       Date:  2004-11-07       Impact factor: 2.474

3.  Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis.

Authors:  Andreas Hoeflich; Brit Fitzner; Christina Walz; Michael Hecker; Armin Tuchscherer; Manuela Bastian; Julia Brenmoehl; Ina Schröder; Holger S Willenberg; Martin Reincke; Uwe Klaus Zettl
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-27       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.